CBDNewsBreaks – HempFusion Wellness Inc. (TSX: CBD.U) (OTCQX: CBDHF) (FWB: 8OO) Announces Completion of Pilot Trial, Releases White Paper

HempFusion Wellness (TSX: CBD.U) (OTCQX: CBDHF) (FWB: 8OO), a leading health and wellness CBD company utilizing the power of whole-food hemp nutrition, has completed a pilot study assessing the effect of its HempFusion formulation CBD Capsules(R) (HempFusion 20mg CBD capsules with botanical terpenes) as it relates to a combination of anti-inflammatories in lowering the results of the chronic inflammation test. The study was conducted in collaboration with Kansas-based Inflammatory Markers Laboratory (“IML”). In addition, the company also released a white paper titled, “Oral Formulation May Modulate Thromboxane Production.” The white paper was s co-authored by IML director Gordon Ens and George Fritsma, a professor at University of Alabama; the paper focuses on the potential of tracking and elucidating biomarkers sensitive to inflammation in addition to how novel compounds and formulas modulate the expression of these markers. Pilot study results showed potential promise in the area of inflammatory markers and possible effects on exaggerated inflammation. “We are committed to furthering research in the area of hemp-derived CBD,” said HempFusion co-founder and CEO Jason Mitchell in the press release. “And this pilot trial and soon to be published white paper reinforces our continued focus on the safe and effective use of hemp-derived CBD products.”

To view the full press release, visit https://cnw.fm/64J35

About HempFusion Wellness Inc.

HempFusion is a leading health and wellness CBD company utilizing the power of whole-food hemp nutrition. HempFusion distributes its family of brands, including HempFusion, Probulin Probiotics, Biome Research and HF Labs, to approximately 4,000 retailers across all 50 states of the United States and select international locations. Built on a foundation of regulatory compliance and human safety, HempFusion’s diverse product portfolio comprises 46 SKUs (“SKUs”) including tinctures, proprietary FDA Drug Listed over-the-counter (“OTC”) topicals, doctor/practitioner lines and more. With a strong focus on research and development, HempFusion has an additional 30 products under development. HempFusion is a board member of the US Hemp Roundtable, and HempFusion’s wholly owned subsidiary, Probulin Probiotics, is one of the fastest-growing probiotics companies in the United States, according to SPINs reported data. HempFusion’s CBD products are based on a proprietary Whole Food Hemp Complex(TM) and are available in store or online. For more information about the company, visit www.HempFusion.com.

NOTE TO INVESTORS: The latest news and updates relating to CBDHF are available in the company’s newsroom at https://cnw.fm/CBDHF

About CBDWire

CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s